Sakar Healthcare Limited has informed the Exchange regarding a press release dated May 12, 2026, titled "Press Release - Consolidated and Standalone Audited Financial Results for the quarter and year ended March 31, 2026".
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sakar Healthcare reported strong Q4FY26 results with revenue of ₹7,110 lakhs, up 42% YoY, backed by new oncology market authorizations and robust demand across export markets. EBITDA surged 67% to ₹2,624 lakhs with a margin of 37%, while PAT more than doubled to ₹1,102 lakhs with a 16% margin — reflecting improved operating leverage and cost discipline. For the full year FY26, revenue grew 42% to ₹25,174 lakhs, EBITDA rose 39% to ₹6,889 lakhs, and PAT jumped 74% to ₹3,048 lakhs. The oncology division is a key growth driver: 125 of 250 dossiers have been submitted globally, 12 marketing authorizations received, and technology transfer projects with major firms like Accord-Intas, Emcure, and Zydus are advancing with site variation approvals in the UK and EU. Management guided that FY27 will see strengthening export momentum and oncology volume ramp-up.
Sakar Healthcare delivered exceptional all-round growth in FY26 with profitability expanding sharply. The strong oncology pipeline, regulatory approvals across regulated markets, and improving margins signal a sustainable growth trajectory that could support a re-rating of the stock.